Hikma Pharmaceuticals (CHIX:HIKL) 3-Year EBITDA Growth Rate : 2.30% (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals 3-Year EBITDA Growth Rate?

Hikma Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2024 was £1.04.

During the past 12 months, Hikma Pharmaceuticals's average EBITDA Per Share Growth Rate was 31.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 2.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hikma Pharmaceuticals was 43.40% per year. The lowest was -4.20% per year. And the median was 14.30% per year.

Competitive Comparison of Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Hikma Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hikma Pharmaceuticals (CHIX:HIKl) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hikma Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines